Autres langues Immutep ADR Nasdaq

Actions

IMMP

US45257L1089

Recherche biotechnologique et médicale

Temps Différé Nasdaq 21:18:35 29/09/2026			Varia. 5j.	Varia. 1 janv.
4,815 ^USD	-1,33%		-14,96%	-91,58%

21/09	Immutep prévoit un regroupement d'actions pour ses American Depositary Shares cotées au Nasdaq	MT
15/09	Le candidat-médicament d'Immutep dispose désormais d'une trajectoire de développement plus claire, selon Jefferies	MT

Autres langues

21/09	Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares
21/09	Immutep : Change to American Depositary Share Ratio
21/09	Immutep Limited(ASX:IMM) dropped from S&P Global BMI Index
21/09	Immutep Limited(ASX:IMM) dropped from S&P/ASX Small Ordinaries Index
21/09	Immutep Limited(ASX:IMM) dropped from S&P/ASX 300 Index
21/09	Immutep Limited(ASX:IMM) dropped from S&P/ASX All Ordinaries Index
17/09	Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma
15/09	Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says
11/09	Immutep Limited Outlines Focused Development Strategy for Eftilagimod Alfa
11/09	Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
11/09	Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial
31/08	Immutep Limited Reports Earnings Results for the Full Year Ended June 30, 2026
30/07	Immutep Quarterly Activities Report Q4 FY26
27/07	Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology Congress 2026
24/07	Immutep : Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
15/07	Immutep highlights encouraging survival data and key clinical milestones
14/07	Immutep Granted New US Patent for Cancer Treatment Methods
14/07	Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14/07	Immutep Receives New US Patent for Cancer Treatment Method; Shares Down 4%
13/07	Immutep Limited Provides Positive Update on INSIGHT-003 Phase I Trial and Discontinues TACTI-004 Phase III Trialin 1 Line Non-Small Cell Lung Cancer
13/07	Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial
13/07	Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
30/06	Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline
17/06	Immutep Shares Rise After Maxim Group Upgrade
10/06	Immutep Says JPMorgan Ceases to Be Substantial Holder